Abacavir is an antiretroviral medication widely used in the treatment of HIV/AIDS. Belonging to the nucleoside reverse transcriptase inhibitor (NRTI) class, abacavir works by inhibiting the reverse transcriptase enzyme, crucial for the replication of the human immunodeficiency virus (HIV). It is often included as part of combination therapy, known as antiretroviral therapy (ART), to enhance treatment efficacy and reduce the risk of drug resistance. One distinctive aspect of abacavir is its potential to cause hypersensitivity reactions, particularly in individuals carrying a specific genetic marker (HLA-B*5701). Prior to initiating abacavir therapy, genetic testing is recommended to identify individuals at risk of severe reactions. Symptoms of hypersensitivity include fever, rash, gastrointestinal issues, and respiratory distress, and if suspected, abacavir should be discontinued immediately. Abacavir is administered orally and has a favorable safety profile when used appropriately. Regular monitoring of HIV viral load and CD4 cell counts is crucial to assess treatment effectiveness. While the medication does not cure HIV/AIDS, it plays a vital role in suppressing the virus, improving immune function, and enhancing the overall quality of life for individuals living with the disease. Ongoing research continues to explore new antiretroviral strategies and improve the management of HIV/AIDS globally.
Title : The role of the humoral innate immune system in evasion of streptococcus pyogenes infections
Francis J. Castellino, University of Notre Dame, United States
Title : Global environmental changes and mosquito-borne diseases in coastal areas
Ranjan Ramasamy, IDFISH Technology, United States
Title : The impact of global antibiotic resistance on the healthcare system, public health, environment and society
Reza Nassiri, Michigan State University, United States
Title : Current topics of adult COVID-19, Influenza, and RS virus patients in Japan
Seki Masafumi, Saitama Medical University International Medical Center, Japan
Title : Novel nanotechnology and its potential applications
Stephen Hsu, Augusta University, United States
Title : 2000 years of pandemics: Past, present and future
Claudia Ferreira, Biophytis Sorbonne, France